Adam Brufsky, MD, PhD, FACP, is Professor of Medicine at the University of Pittsburgh School of Medicine and also serves as the Associate Division Chief for the Division of Hematology/Oncology at the University of Pittsburgh School of Medicine’s Department of Medicine. Dr. Brufsky is the Medical Director of the Women’s Cancer Center at Magee-Women’s Hospital of University of Pittsburgh Medical Center and the University of Pittsburgh Cancer Institute (UPCI); Associate Director for clinical investigations at UPCI; and Codirector of the Comprehensive Breast Cancer Center.
Dr. Brufsky is board-certified in internal medicine and medical oncology. He earned his medical degree and doctor of philosophy from the University of Connecticut School of Medicine in Farmington, Connecticut, completed a residency at Brigham and Women’s Hospital/Harvard Medical School, and a fellowship at Dana-Farber Cancer Institute, both located in Boston, Massachusetts.
Dr. Brufsky is a member of several professional organizations, such as the American Medical Association, the Massachusetts Medical Society, the American College of Physicians, and the American Society of Clinical Oncology. An active researcher, he has published numerous abstracts and research articles in leading journals, and is principal investigator on a number of research grants funded by the National Institutes of Health, Susan G. Komen Foundation, and US Army-Breast Cancer Research Program.
FACULTY DISCLOSURE
Adam Brufsky, MD, PhD, FACP, has served as a consultant for Genetech/Roche.
乳がんの分子標的治療がもたらす症状緩和と臨床的有用性
要約
再発・転移性乳がんに対する多くの新規分子標的治療薬は無増悪期間、生存期間を延長させる可能性がある。これらの治療薬は再発・転移性乳がん患者が抱えている辛い症状をほとんど副作用なく、軽減させることが可能であるが、まだ広く議論されていない。患者のPSが良好な時期からより低下する臨床経過の中で、または症状緩和を主要な目的とする場面で、これらの薬剤が使われることは認められると思われる。
本講演では再発・転移性乳がんに対して、現在、使われている分子標的治療薬について概略するが、強調する点は患者のどのような状態、時期においても、これらの薬剤が多大な症状緩和をもたらし、QOLを改善するということである。
(邦訳：大村東生)
